Top

Published in:

01-03-2008 | Hepatic and Pancreatic Tumors

Tumor-Associated Lymphangiogenesis Correlates with Lymph Node Metastases and Prognosis in Hilar Cholangiocarcinoma

Authors: Armin Thelen, MD, Arne Scholz, MD, Christoph Benckert, MD, Wilko Weichert, MD, Ekkehart Dietz, MD, Bertram Wiedenmann, MD, PhD, Peter Neuhaus, MD, PhD, Sven Jonas, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2008

Abstract

Background

Tumor-associated lymphangiogenesis has been shown to promote nodal spread and is of prognostic significance in some tumor entities. Currently, nothing is known about the impact of lymphangiogenesis on progression and prognosis in hilar cholangiocarcinoma.

Methods

We analyzed tissue specimens of normal liver and hilar cholangiocarcinoma (n = 60) by immunohistochemistry using the lymphendothelial-specific antibody D2-40 and subsequently quantified lymphatic microvessel density (LVD). The LVD was correlated with clinicopathological characteristics and recurrence pattern of the tumors as well as patients’ survival.

Results

In contrast to the low abundance of lymphatic vessels in nontransformed liver tissue, we found an induction of lymphangiogenesis in hilar cholangiocarcinoma. Tumors with a high LVD (34 out of 60) had a significant higher incidence of lymph node involvement (p < 0.001), perivascular (p = 0.017), and perineural (p = 0.033) lymphangiosis and local recurrence (p < 0.001). Furthermore, a high LVD was identified to be a significant overall (three-year: 24.4% versus 90.5%; five-year: 7.0% versus 76.4%; p < 0.001) and disease-free (three-year: 8.3% versus 76.6%; five-year: 5.9% versus 61.4%; p < 0.001) survival disadvantage, with LVD representing an independent prognostic factor for survival (p < 0.001) in the multivariate analysis.

Conclusions

Lymphangiogenesis is associated with increased frequency of tumor cells in lymphatics and lymph nodes in hilar cholangiocarcinoma. The prognostic importance of tumor-associated lymphangiogenesis was reflected by LVD serving as an independent prognostic factor. In addition, lymphangiogenesis may represent a potential target in the development of new therapeutic approaches in hilar cholangiocarcinoma.

Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946–53PubMedCrossRef

Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18:143–52PubMedCrossRef

Renyi-Vamos F, Tovari J, Fillinger J, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 2005;11:7344–53PubMedCrossRef

Franchi A, Gallo O, Massi D, et al. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 2004;101:973–8PubMedCrossRef

Zeng Y, Opeskin K, Horvath LG, et al. Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 2005;65:222–30PubMedCrossRef

Kahn HJ, Marks A. A new monoclonal antibody, D2–40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255–7PubMed

Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913–21PubMed

Brundler MA, Harrison JA, de Saussure B, et al. Lymphatic vessel density in the neoplastic progression of Barrett’s oesophagus to adenocarcinoma. J Clin Pathol 2006;59:191–5PubMedCrossRef

Neuhaus P, Jonas S. Surgery for hilar cholangiocarcinoma–the German experience. J Hepatobiliary Pancreat Surg 2000;7:142–7PubMedCrossRef

10.

Neuhaus P, Jonas S, Settmacher U, et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg 2003;388:194–200PubMedCrossRef

11.

Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33–42PubMedCrossRef

12.

Ortner MA, Dorta G. Technology insight: Photodynamic therapy for cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:459–67PubMedCrossRef

13.

Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006;2:509–14PubMedCrossRef

14.

Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 2005;241:77–84PubMed

15.

Wiley J, Sons. UICC. TNM Classification of Malignant Tumors. 6th ed. New York: Springer, 2002

16.

Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997;15:947–54PubMed

17.

Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808–19PubMedCrossRef

18.

Abdel Wahab M, Fathy O, Elghwalby N, et al. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology 2006;53:5–10PubMed

19.

Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–17PubMedCrossRef

20.

Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238:720–7PubMedCrossRef

21.

Ramacciato G, Di Benedetto F, Cautero N, et al. Prognostic factors and long term outcome after surgery for hilar cholangiocarcinoma. Univariate and multivariate analysis. Chir Ital 2004;56:749–59

22.

Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883–6PubMedCrossRef

23.

Kimura W, Nagai H, Atomi Y, et al. Clinicopathological characteristics of hepatic hilar bile duct carcinoma. Hepatogastroenterology 1993;40:21–7PubMed

24.

Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306–12PubMedCrossRef

25.

Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006;12:800–6PubMedCrossRef

26.

Nakamura Y, Yasuoka H, Tsujimoto M, et al. Importance of lymph vessels in gastric cancer: a prognostic indicator in general and a predictor for lymph node metastasis in early stage cancer. J Clin Pathol 2006;59:77–82PubMedCrossRef

27.

Hirakawa S, Kodama S, Kunstfeld R, et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005;201:1089–99PubMedCrossRef

28.

Achen MG, Stacker SA. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer 2006;119:1755–60PubMedCrossRef

29.

Schoppmann SF, Birner P, Stöckl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947–56PubMed

30.

Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003;63:1083–92PubMed

31.

Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005;97:14–21PubMedCrossRef

32.

He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819–25PubMed

33.

Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186–91PubMedCrossRef

34.

Ahmed SI, Thomas AL, Steward WP. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 2004;16:59–63PubMed

Title: Tumor-Associated Lymphangiogenesis Correlates with Lymph Node Metastases and Prognosis in Hilar Cholangiocarcinoma
Authors: Armin Thelen, MD
Arne Scholz, MD
Christoph Benckert, MD
Wilko Weichert, MD
Ekkehart Dietz, MD
Bertram Wiedenmann, MD, PhD
Peter Neuhaus, MD, PhD
Sven Jonas, MD, PhD
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 3/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9774-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tumor-Associated Lymphangiogenesis Correlates with Lymph Node Metastases and Prognosis in Hilar Cholangiocarcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

Analysis of Risk Factors of Predictive Local Tumor Control in Oral Cavity Cancer

Reducing Local Recurrence after Breast-Conserving Surgery for Breast Cancer

Atypical Ductal Hyperplasia at Margin of Breast Biopsy—Is Re-Excision Indicated?

The Influence of Age on the Breast Surgery Decision-Making Process

Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers

Comparison Between the Minimum Margin Defined on Preoperative Imaging and the Final Surgical Margin After Hepatectomy for Cancer: How to Manage It?